Search Results for: DNA VACCINE TECHNOLOGY A Vaccine
Articles
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer February 24, 2021
Celsion Corporation recently announced that it has received Fast Track designation from the US FDA for GEN-1, its DNA-mediated interleukin-12...Maravai LifeSciences Expands Its Intellectual Property Portfolio February 11, 2021
Maravai LifeSciences, Inc. recently announced the United States Patent and Trademark Office has issued a new patent, United States Patent No. 10,913,768, to the company’s TriLink Biotechnologies subsidiary…..
Evaxion Biotech Launches New AI Powered Platform to Enable Faster Response to Emerging Viral Pandemics October 7, 2020
Evaxion Biotech recently announced it has received approximately $800,000 in funding from Innovation Fund Denmark for the development of its...SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Specialized Capabilities for Small & Large Molecules June 4, 2020
Contributor Cindy H. Dubin interviews key players in the CDMO market who present case studies about how they are helping pharmaceutical and biopharma companies overcome a variety of formulation and manufacturing challenges.
GENE THERAPY - The Role Viral Vectors Play in Current Gene Therapy Development June 4, 2020
Dieter Lingelbach, MBA, discusses the history and science of viral vectors, their current applications, and why they are a vital component in contemporary gene therapy development.
CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement June 2, 2020
CordenPharma recently announced the signing of an amendment to their existing manufacturing agreement with Moderna, Inc., a clinical stage biotechnology...Novavax’s NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial March 25, 2020
Novavax, Inc. recently announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal...PERSONALIZED MEDICINE - Personalizing Cancer Immunotherapy: Trends in Biomarker Discovery January 14, 2020
Emile Youssef, MD, PhD, says due to tumor heterogeneity, the plasticity and diversity of cancer cells, and a multitude of other factors, biomarker development is a challenge, and thus explores four trends in cancer biomarker discovery.
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial December 4, 2019
Soligenix, Inc. recently announced it has completed patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study...Novel Silica Delivery System Enters Final Preclinical Development Stage October 3, 2019
N4 Pharma Plc recently announced results from the company’s latest research study into its novel silica nanoparticle for cancer treatments...INTRATUMORAL DELIVERY - Arming the Immune System; Turning Cold Tumors Hot August 29, 2019
Daniel J. O’Connor believes a trigger mechanism that can turn cold tumors hot can help researchers set their focus on delivering potentially life-saving drugs directly to core of a cancerous tumor.
Amicus Therapeutics & Catalent Biologics Enter Strategic Partnership July 2, 2019
Amicus Therapeutics, Inc. has entered into a strategic manufacturing agreement with Paragon Gene Therapy, a unit of Catalent Biologics, for clinical manufacturing capabilities and capacity for….
Novavax & Catalent Biologics Enter Strategic Partnership June 26, 2019
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit recently announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to……..
Up to 6 New HBV Drugs Set to Launch by 2027, With China Driving Market Growth May 30, 2019
Within the next 10 years, up to 6 new drugs are projected to be approved for the treatment of chronic...SPECIAL FEATURE - Prefilled Syringes & Parenteral Manufacturing: Flexibility for Faster Development April 30, 2019
Contributor Cindy H. Dubin interviews several contract manufacturers and device developers who are responsible for creating next-generation parenteral drug delivery.
Paragon Bioservices to be Acquired for $1.2 Billion April 15, 2019
Catalent, Inc. and Paragon Bioservices, Inc. and Catalent Inc. recently announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.
Inovio Closes License & Collaboration Agreement With ApolloBio March 23, 2018
Inovio Pharmaceuticals, Inc. recently announced it has closed an agreement providing ApolloBio Corp. with the exclusive right to develop, manufacture,...Inovio Enters License & Collaboration Agreement With ApolloBio January 8, 2018
Inovio Pharmaceuticals, Inc. recently announced it entered an amended agreement providing ApolloBio Corporation with the exclusive right to develop and...Arcturus Therapeutics & Synthetic Genomics Announce Strategic Alliance November 6, 2017
Arcturus Therapeutics, Inc. and Synthetic Genomics, Inc. recently announced they have entered into a research collaboration and worldwide license agreement...GENE & CELL THERAPY - Its Growing Potential to Disrupt Drug Research & Healthcare Delivery October 2, 2017
Jeff Galvin believes as the pace of gene and cell therapies accelerates over this next decade, potential cures for chronic diseases, cancer cures, and autosomal defect cures will result, and the efficacy of new therapeutics may move as much as $500 billion from traditional pharmaceuticals to gene technologies.